XENETIC BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.956 USD | +4.09% |
|
+0.78% | +14.65% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6.25 | 13.05 | 12.77 | 3.575 | 4.176 | 4.811 | - | - |
| Enterprise Value (EV) 1 | 6.25 | 13.05 | 12.77 | 3.575 | 4.176 | 4.811 | 4.811 | 4.811 |
| P/E ratio | -0.23 x | -1.2 x | -2.35 x | -0.62 x | -1.27 x | -4.12 x | -5.42 x | -5.73 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 445 x | 41.5 x | 14.6 x | 2.56 x | 2.08 x | 2.74 x | 3.35 x | 2.62 x |
| EV / Revenue | 445 x | 41.5 x | 14.6 x | 2.56 x | 2.08 x | 2.74 x | 3.35 x | 2.62 x |
| EV / EBITDA | - | -1.3 x | -2.94 x | -0.65 x | -1.17 x | -1 x | -0.58 x | -0.36 x |
| EV / FCF | -594,015 x | - | - | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 576 | 875 | 1,339 | 1,517 | 1,541 | 1,541 | - | - |
| Reference price 2 | 14.40 | 20.40 | 12.90 | 2.851 | 3.450 | 3.956 | 3.956 | 3.956 |
| Announcement Date | 26/03/20 | 16/03/21 | 22/03/22 | 22/03/23 | 21/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.0141 | 0.3146 | 0.876 | 1.396 | 2.005 | 1.758 | 1.438 | 1.838 |
| EBITDA 1 | - | -10.04 | -4.337 | -5.492 | -3.564 | -4.795 | -8.311 | -13.18 |
| EBIT 1 | -10.62 | -10.04 | -4.337 | -5.492 | -3.564 | -4.795 | -8.311 | -13.18 |
| Operating Margin | -75,512.59% | -3,189.84% | -495.12% | -393.57% | -177.78% | -272.75% | -577.96% | -717.36% |
| Earnings before Tax (EBT) 1 | -10.52 | -9.946 | -4.26 | -5.357 | -3.264 | -4.555 | -7.991 | -12.95 |
| Net income 1 | -14.88 | -7.844 | -4.26 | -5.357 | -3.264 | -4.555 | -7.991 | -12.94 |
| Net margin | -105,822.19% | -2,493.13% | -486.36% | -383.87% | -162.78% | -259.1% | -555.7% | -704.3% |
| EPS 2 | -63.30 | -17.00 | -5.500 | -4.600 | -2.710 | -0.9600 | -0.7300 | -0.6900 |
| Free Cash Flow | -10.52 | - | - | - | - | - | - | - |
| FCF margin | -74,832.86% | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 26/03/20 | 16/03/21 | 22/03/22 | 22/03/23 | 21/03/24 | - | - | - |
1GBP in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.251 | 0.3181 | 0.3412 | 0.363 | 0.3981 | 0.4842 | 0.5114 | 0.4976 | 0.5304 | 0.4082 | 0.432 | 0.455 | 0.479 |
| EBITDA 1 | -1.414 | -1.324 | -2.2 | -0.7429 | -1.278 | -0.7314 | -0.9412 | -0.9336 | -0.9911 | -1.014 | -1.119 | -1.279 | -1.438 |
| EBIT 1 | -1.414 | -1.324 | -2.2 | -0.7429 | -1.278 | -0.7314 | -0.9412 | -0.9336 | -0.9911 | -1.014 | -1.119 | -1.279 | -1.438 |
| Operating Margin | -563.44% | -416.38% | -644.82% | -204.66% | -321.03% | -151.06% | -184.05% | -187.62% | -186.87% | -248.31% | -259.03% | -281.1% | -300.21% |
| Earnings before Tax (EBT) 1 | -1.39 | -1.303 | -2.188 | -0.7045 | -1.212 | -0.6845 | -0.8256 | -0.8594 | -0.9247 | -0.955 | -1.039 | -1.199 | -1.358 |
| Net income 1 | -1.39 | -1.303 | -2.188 | -0.7045 | -1.212 | -0.6845 | -0.8256 | -0.8594 | -0.9247 | -0.955 | -1.039 | -1.199 | -1.358 |
| Net margin | -553.71% | -409.67% | -641.25% | -194.09% | -304.44% | -141.38% | -161.44% | -172.71% | -174.34% | -233.96% | -240.51% | -263.52% | -283.51% |
| EPS 2 | -1.400 | -1.200 | -1.900 | -0.6000 | -1.000 | -0.6000 | -0.6900 | -0.6900 | -0.7700 | -0.7800 | -0.8300 | -0.1500 | -0.1600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22/03/22 | 12/05/22 | 11/08/22 | 09/11/22 | 22/03/23 | 11/05/23 | 10/08/23 | 09/11/23 | 21/03/24 | 09/05/24 | - | - | - |
1GBP in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -10.5 | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 26/03/20 | 16/03/21 | 22/03/22 | 22/03/23 | 21/03/24 | - | - | - |
1GBP in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3.956
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.65% | 6.09M | |
| +7.52% | 113B | |
| +11.38% | 106B | |
| -12.64% | 22.22B | |
| +0.47% | 22.27B | |
| -4.08% | 19.43B | |
| -37.85% | 17.87B | |
| -8.58% | 17.24B | |
| +37.41% | 12.52B | |
| -23.95% | 8.34B |
- Stock Market
- Equities
- XBIO Stock
- Financials Xenetic Biosciences, Inc.
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**As early as today, start finding the best investment opportunities!**#ffffff**/registration/member/**#004eff**#000000**Optimize my profits**1**
